ILTS 2019 Consensus Conference: Transplant Oncology – the Future of Multidisciplinary Management

Consensus Conference by ILTS:
Thursday, February 7, 2019
Hilton Rotterdam

Transplant oncology is a new concept encompassing multiple disciplines of transplantation medicine and oncology to take hepatobiliary cancer treatment and research to the next level. The Consensus Conference in Rotterdam convened worldwide experts and opinion leaders in transplant surgery, radiology and oncology, hepatology and immunology to discuss the frontiers and future perspectives of multidisciplinary management of hepatobiliary malignancies.

The main topics included liver transplantation for hepatocellular carcinoma, cholangiocarcinoma, colorectal and neuroendocrine liver metastases, pediatric malignancy, therapies for cancer recurrence after liver transplantation and the role of novel chemotherapeutic and biological agents to enhance transplantation outcomes.

After a morning of inspiring lectures, delegates joined afternoon working groups with the task of finding solutions and suggesting guidelines for topic-related issues.


The Program

Introductory Lectures (8:00 – 9:30):

  • Transplant oncology – Current perspectives
    John Roberts, MD University of California San Francisco – San Francisco, CA, USA
  • The future of transplant oncology: Bridging the Gap
    Vincenzo Mazzaferro, MD, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano – Milan, Italy
    Bruno Sangro, MD, PhD The University of Navarra School of Medicine – Pamplona, Spain
  • Novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches
    R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA
    Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

Consensus Conference Lectures (9:30 – 13:00)

  • The update of liver transplantation for HCC
    Western experience:
    Francis Yao, MD University of California: San Francisco – San Francisco, CA, USA
    Eastern experience:
    Avi Soin, MD Medanta – The Medicity, India
  • The update of liver transplantation for CCA
    Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA
    Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
  • Emerging indications for liver transplantation: colorectal and neuroendocrine liver metastases
    James Eason, MD Methodist University Transplant – Memphis, TN, USA
    Pal Dag Line, MD, PhD Oslo University Hospital – Oslo, Norway
  • Pediatric transplant oncology
    Mohamed Rela, MD Gleneagles Global Hospital – Chennai, India
    Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences – Kumamoto, Japan
  • Post-transplant management for cancer recurrence
    Sherrie Bhoori, MD National Cancer Institute – Milan, Italy
    Shusen Zheng, MD, PhD Zhejiang University – Hangzhou, China
  • The changes of transplant indications
    DAA therapies
    Marina Berenguer, MD Hospital La Fe – Valencia, Spain
    NASH/HCC
    Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy

Working group discussion (14:00 – 15:30)

  1. Liver transplantation for HCC
    – Updates on the selection criteria
    – Prediction models
    – Downstaging and bridging therapies
    – Should small tumors be treated by ablation and reserve OLT for large cancers?
    Group leaders: Vincenzo Mazzaferro, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy
    Neil Mehta, PhD University of California: San Francisco – San Francisco, CA, USA
    Avi Soin, MD Medanta – The Medicity, India

  2. Liver transplantation for CCA /mixed HCC/CCA
    – Hilar CCA
    – Intrahepatic CCA
    – Mixed HCC/CCA (Outcomes, diagnostic and prognostic tools, adjuvant treatments)
    Group Leaders: Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA
    Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
    Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

  3. Less common tumors of transplant oncology
    a. Colorectal liver metastasis
    b. Neuroendocrine liver metastasis
    c. Tumors in the pediatric population and other rare tumor
    Group Leaders: Mohamed Rela, MD Gleneagles Global Hospital – Chennai, India
    Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences Kumamoto, Japan
    James Eason, MD Methodist University Transplant – Memphis, TN, USA

  4. Post-transplant management
    a. Tailored immunosuppression for cancer recipients
    b. Cancer recurrence prediction models and surveillance strategies
    c. New adjuvant therapies for recurrence after OLT (chemotherapy, immunotherapy, new biological treatment and radiotherapy)
    Group Leaders:Marina Berenguer, MD Hospital La Fe – Valencia, Spain
    Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy
    Herold Metselaar, MD, PhD Erasmus MC – Rotterdam, The Netherlands

Working group presentations with statements (16:00 -18:00)

Summary (18:00-18:30)

Download the detailed Program here.


CONTINUING MEDICAL EDUCATION (CME) CREDITS

The ILTS 2019 Consensus Conference: Transplant Oncology – The Future of MultidisciplinaryManagement, Rotterdam, Netherlands, 07/02/2019-07/02/2019 has been accredited by theEuropean Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CMEcredits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/sheactually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the AmericanMedical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRACategory 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can befound at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® forECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by theMaintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.


Ethical MedTech Assessments

ILTS 2019 Consensus Conference: Transplant Oncology – the Future of Multidisciplinary Management is now compliant with the MedTech Europe Code of Ethical Business Practice www.ethicalmedtech.eu.

After rigorous selection, K.I.T. Group GmbH is among the first organisations to earn the Medtech Ethical Charter. This is the official certification of those PCOs that demonstrate understanding and commitment to the new regulations. (https://www.ethicalmedtech.eu/ethical-charter/chartered-organisations/).

Working with K.I.T. Group GmbH, an officially licensed Medtech Trusted Partner, will offer very real advantages to Medtech member companies, medical societies, conference venues and hotels. Read more here.


AIFA – The official agency for Italian delegates and industry:

Barbara Mantegazza Aria di Viaggi Srl – Congress and Fair Department
Via Matteo Bandello, 1 – 20123 Milano
P.I. 02818040152 – IATA 38220346
Tel. +39 02.4818691
www.ariadiviaggi.it   
barbara.mantegazza@ariadiviaggi.it

The ILTS Consensus Conference was supported by:

Event details: - Hilton Rotterdam